Treatment Adherence in Adolescents with Asthma by Kaplan, Alan & Price, David
R E V I EW
Treatment Adherence in Adolescents with Asthma
This article was published in the following Dove Press journal:
Journal of Asthma and Allergy
Alan Kaplan1–3
David Price3,4
1University of Toronto Department of
Family and Community Medicine,
Toronto, ON, Canada; 2Family Physician
Airways Group of Canada, Edmonton,
AB, Canada; 3Observational and
Pragmatic Research Institute, Singapore,
Singapore; 4Centre of Academic Primary
Care, Division of Applied Health
Sciences, University of Aberdeen,
Aberdeen, UK
Abstract: The burden of asthma is particularly notable in adolescents, and is associated with
higher rates of prevalence and mortality compared with younger children. One factor
contributing to inadequate asthma control in adolescents is poor treatment adherence, with
many pediatric studies reporting mean adherence rates of 50% or lower. Identifying the
reasons for poor disease control and adherence is essential in order to help improve patient
quality of life. In this review, we explore the driving factors behind non-adherence in
adolescents with asthma, consider their consequences and suggest possible solutions to
ensure better disease control. We examine the impact of appropriate inhaler choice and
good inhaler technique on adherence, as well as discuss the importance of selecting the right
medication, including the possible role of as-needed inhaled corticosteroids/long-acting β2-
agonists vs short-acting β2-agonists, for improving outcomes in patients with mild asthma
and poor adherence. Effective patient/healthcare practitioner communication also has
a signiﬁcant role to engage and motivate adolescents to take their medication regularly.
Keywords: asthma, adherence, adolescents, treatment
Plain Language Summary
Asthma is particularly serious for adolescents. Asthma is more common in this age
group, and more adolescents than younger children die due to asthma. One reason for
this is that around half of adolescents with asthma do not take their medication properly.
It is important to understand why this happens in order to improve their outlook and
quality of life. Here, we look at the range of reasons for why adolescents do not take
their asthma medications properly and the results of this. These include adolescents
becoming more independent and wanting to be responsible for taking their medication,
but sometimes forgetting to take it or being embarrassed to take it in front of their
friends. We also discuss possible answers. These include why using the right inhaler and
learning to use it effectively is important. Choosing the best treatment to suit each person
is also critical. We look at how doctors can communicate better with adolescents to
engage and motivate them to take their medication regularly.
Introduction
Asthma is recognized as the most common non-communicable disease in children
worldwide,1 affecting approximately 8.4% of children and adolescents in the US
and 9.1% in the UK,2,3 although data from the International Study of Asthma and
Allergies in Childhood indicate that the prevalence of asthma symptoms in young
people varies considerably between countries.4 The burden of asthma is particularly
high in adolescents, with an increased prevalence and mortality compared with
younger children.5–7 For example, in the US between 1980 and 2007, the number of
asthma-related deaths was 1.9 per 1 million children aged 0–4 years, rising to
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2.8 per 1 million children aged 11–17 years, respectively,
with prevalence rising from 6.2% to 10.0% between the
two age groups.6
Irrespective of age, the aim of asthma therapy is to
achieve good symptom control, and to minimize the risk of
future exacerbations, ﬁxed airﬂow limitation and side
effects of treatment.8 Treatment strategies recommended
by the Global Initiative for Asthma (GINA) are tailored
according to age, with separate recommendations for
adults, adolescents and children aged 6–11 years versus
those ≤5 years.8 However, despite the availability of effec-
tive treatments such as inhaled corticosteroids (ICS), long-
acting β2-agonists and long-acting muscarinic antagonists,
many children and adolescents with asthma remain
uncontrolled.9 Many factors inﬂuence the success of treat-
ment and of achieving disease control, such as asthma
triggers, comorbidities and asthma phenotype.10 Other
inﬂuences may be related to the physician (eg, not follow-
ing guidelines, assessing the patient inappropriately, or
inadequate choice of treatment or inhaler device) or the
patient (eg, sociodemographic factors, exposure to cigar-
ette smoke, poor treatment adherence, and inadequate
inhaler technique or disease education).10,11 Additional
contributing factors may relate to the healthcare system,
such as medicinal coverage and spirometry testing.12
Although estimates vary, adherence to prescribed therapy
is generally low in adolescents and children (~30–70%), as
described in more detail below. Non-adherence is particu-
larly concerning in adolescents, who have speciﬁc age-
related barriers to taking their medication, which can have
a disastrous impact on asthma control and subsequent
outcomes.5,13–18 The aim of this review is to understand the
driving factors behind non-adherence in adolescents with
asthma, their consequences and possible solutions to ensure
better disease control.
Classiﬁcation of Adherence/
Non-Adherence
Adherence is deﬁned by the World Health Organization as
“the extent to which a person’s behavior – taking medica-
tion, following a diet, and/or executing lifestyle changes,
corresponds with agreed recommendations from a health
care provider.”19 Traditionally, adherence has been evalu-
ated from the patient perspective, although more recent
models have a more prominent role for healthcare profes-
sionals (HCPs).20
There are several stages where adherence to treatment
can fail, as illustrated in Figure 1. Non-adherence can be
divided into three distinct temporal phases: failure to
initiate treatment, failure to implement treatment cor-
rectly, and non-persistence with treatment.21 Initiation
(ie, when the patient takes their ﬁrst dose of
a prescribed medication) is typically a binary event,
with patients either starting to take their medication or
not.21 The second step – implementation – can be deﬁned
as the extent to which a patient’s actual dosing corre-
sponds with their prescribed dosing regimen over time,
from initiation until the last dose is taken.21 This involves
taking the medication as directed, which, in asthma,
includes inhaler technique. Persistence – the ﬁnal step –
refers to the time that elapses between initiation and
eventual treatment discontinuation.21 After this time
point, a period of non-persistence may follow until the
end of the intended prescribing period.
Non-adherence may either be deliberate or accidental.22
Deliberate or intentional non-adherence refers to patients
missing or altering doses to suit their own needs, and includes
an unwillingness to take medication as prescribed and not
attending medical appointments. Accidental or unintentional
non-adherence, however, includes unknowingly using the
inhalation device incorrectly or forgetting to take medication
as prescribed.19,22
It should be noted that non-adherence can be difﬁcult to
measure. General problems with evaluating adherence include
the fact that there is currently no gold standard available, while
some of the available methods are inaccurate, biased or
costly.18,21 In addition, a high rate of variability is observed
when calculating adherence rates, possibly due to differences
between study populations, including race and age.18
Physician assessment of adherence is often inaccurate (eg,
using closed- rather than open-ended questioning), and patients
or caregivers may be reluctant to admit to non-adherence,
contributing further to the difﬁculties in quantiﬁcation.18
Although this review focuses speciﬁcally on medication
adherence, it should be noted that non-adherence to asthma
trigger modiﬁcation is also a recurrent problem in clinical
practice that needs to be addressed.23 Findings from a 2-year
retrospective cohort study showed that advice for managing
asthma triggers was given in only 30% of visits and adher-
ence to trigger advice was evaluated at only 6% of visits.23
These results show that asthma trigger management is sub-
optimal across multiple healthcare settings and should be
a target for improvement in routine asthma outpatient
visits.23
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Prevalence of Non-Adherence in
Adolescents
Although adolescents are less studied than other populations,
the few studies carried out in this age group show a substantial
reduction in adherence compared with younger children or
older patients with asthma.5,13–18,24,25 However, estimates
vary from study to study, in part because of the range of
methods available to evaluate adherence. These include both
subjective and objective methods, as well as electronic mon-
itoring devices, which represent the current gold standard for
monitoring adherence.26
Several studies have been carried out using electronic
monitoring devices. In a 6-month prospective study evaluating
27 children aged 7–12 years with mild-to-moderate asthma,
adherence (evaluated using a metered-dose inhaler equipped
with an electronic doser attached to their ICS) was found to
decrease signiﬁcantly with increasing age.13 Similar results
were seen in a 1-month study of 106 children with asthma,
which used electronic monitoring to measure medication
adherence and also found a negative relationship between
adherence and age.24 However, despite reduced adherence,
adolescents in this study reported signiﬁcantly increased
knowledge and reasoning about asthma, and claimed to take
greater responsibility for asthma management, compared with
their younger counterparts.24 According to a review of pedia-
tric asthma studies using electronic adherence monitoring,
mean adherence rates are largely below 75%, while as many
as half report rates of 50% or lower.15 For example, ﬁndings
from an observational cohort study of 40 15–18-year-olds
with asthma who were prescribed ﬂuticasone/salmeterol,
which was electronically monitored between visits, indicated
a median treatment adherence of 43%, with signiﬁcantly
better adherence reported in the younger versus older
participants.14
Although electronic adherence monitoring is widely
considered to be more accurate than many other methods,
several studies have looked at alternative ways of monitor-
ing adherence. For example, a population-based cohort
study of Dutch children aged 5–18 years evaluated adher-
ence in terms of medication possession ratio and ratio of
controller to total asthma drug, deriving data from a large
primary care database (N>14,000).17 Using this approach,
only 33% of ICS users were found to regularly use their
inhaler more than 80% of the time.17 Studies using tele-
phone interviews and retrospective analysis of prescription
Figure 1 Stages of medication adherence: initiation, implementation and persistence. Reprinted from The Journal of Allergy and Clinical Immunology: In Practice, 4/5,
Vrijens et al, What We Mean When We Talk About Adherence in Respiratory Medicine, 802–812, 2016, with permission from Elsevier.
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ﬁlls indicate that adherence to oral corticosteroids after
emergency department visits is also lower in adolescents
compared with younger patients.27,28
Some studies where adherence rates were self-reported
by adolescents or parents gave higher estimates, although
it should be noted that this method tends to give inﬂated
ﬁgures compared with other measures.13 One study indi-
cated a 77% rate of adherence to asthma treatment in
adolescents, versus 92% in children.25 In another study,
adherence recorded from interviews/surveys with adoles-
cents and caregivers was 60% and 69%, respectively.16
Assuming that an adherence level of >75–80% is clinically
relevant in terms of reducing asthma exacerbations,5,29
even these self-reported estimates of adherence in adoles-
cents are insufﬁcient for effective treatment.
Driving Factors Behind
Non-Adherence in Adolescents
As described above, there are a number of stages during
which treatment adherence can be affected. When consid-
ering adherence in asthma speciﬁcally, additional com-
plexity is provided by the variable nature and seasonality
of the condition, which further complicates medication
adherence due to ﬂexible dosage recommendations pro-
vided in self-management plans.21
Treatment initiation in asthma can be affected by a range
of psychologic and practical barriers, including denial of
asthma diagnosis, lack of disease awareness, lack of trust
in HCPs, medication fears, stigma around using inhalers,
cognitive ability, affordability and access to therapy.30 In
terms of treatment implementation and persistence, chal-
lenges regarding the mode of delivery of maintenance treat-
ment represent a major barrier to adherence.30
Below, we review in more detail the different factors
that can affect medication adherence in asthma, both in
general and speciﬁcally in adolescents. This information is
also summarized in Table 1.
General Factors Affecting
Non-Adherence
Asthma regimens often require planning and forethought,
including ﬁlling prescriptions and taking treatment appro-
priately and at the correct time. Inadequate instructions, or
a regimen that is too complex or time-consuming (eg,
multiple components or dosing several times a day), are
important considerations that can affect adherence. In
addition, lack of a structured home environment with
clearly structured routines is a challenge for successful
daily treatment regimens.18 The hectic schedules of
patients and caregivers, or parents living in separate
households with insufﬁcient communication and coordina-
tion between them, can all affect adherence.14,18
Lack of education and negative perceptions about treat-
ment and providers also frequently inﬂuence adherence.
Concerns for patients with asthma include the unpalatable
taste of ICS, fear of side effects and worries about addiction/
dependence.14 Education is also required to learn how to
administer the treatment correctly. Incorrect inhaler use, in
particular, caused by poor coordination, is common and is
associated with decreased lung deposition of ICS, leading to
poor asthma control.31 Patients may also be confused by the
difference between rescue and controller medication, leading
to unintentional poor adherence.18Moreover, patientsmay also
be less inclined to take medication to prevent or reduce risks
rather than taking medication for immediate symptoms.14
These problems are compounded by physician-related issues,
such as poor rapport with patients.18 In particular, studies
suggest that between 39% and 85% of HCPs are unable to
demonstrate and educate patients in the proper use of their
inhaler devices.30
Asthma has also been found to affect the mental health of
affected individuals,32 and studies have shown that depres-
sion and anxiety disorders are associated with increased
functional impairment, which can have an adverse impact
on adherence.33 In terms of symptom perception, 15–60% of
patients are not able to recognize asthma symptoms,34
whereas others may tolerate asthma symptoms that most
HCPs would ﬁnd unacceptable.35 This may include accept-
ing mild asthma exacerbations as normal, or attributing their
asthma symptoms to other causes,35 and is associated with
a heavy burden in terms of hospitalizations and emergency
department visits.36 Alexithymia, a condition characterized
by an inability to identify and express emotions, has also
been associated with inadequate treatment adherence.32
Factors Speciﬁc to Adolescents
It is apparent that different challenges to adherence exist at
successive developmental stages.37 As children with
asthma become adolescents, the barriers impeding good
adherence start to change. While younger children rely on
caregivers and parents for the administration of asthma
medication,18 adolescence is the age during which children
begin to claim more independence and responsibility,
which may in turn affect adherence.13,37 They begin to
form individual opinions and beliefs about their health,
Kaplan and Price Dovepress
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and develop organizational skills and self-regulatory beha-
vior that can signiﬁcantly contribute to adherence.
However, since adolescents often reject parental monitor-
ing and support at this stage, parent–child conﬂict and
confusion over who is responsible for ensuring that med-
ications are taken correctly may follow, with adherence
commonly suffering.37 Involvement in decision-making
around medication use is key to ensure effective initiation,
implementation and persistence with asthma medications,
but lack of engagement by adolescents in this process can
put adherence at risk.37
In contrast, some adolescents still rely on their parents/
caregivers and struggle to take responsibility for their asthma
management,38,39 and so parental motivation may still
remain important for adherence.18 This can be challenging
since chronic diseases such as asthma can place an emotional
and ﬁnancial burden on the family.18Maternal depression has
been linked with a number of factors that can affect
their children’s adherence to asthma medication, including
negative beliefs about asthma therapy, and lack of under-
standing about the function of asthma medications or how to
use them effectively.40
The ease of use and acceptance of the inhaler device plays
an important role in adherence in adolescents. In the UK,
there is evidence that most adolescents, even those with
uncontrolled severe asthma, have poor adherence to taking
their medication as prescribed.39 This intentional non-
adherence is associated with other factors, such as not
being bothered, being too time-consuming or conﬂicting
with other activities, as well as a lack of perceived effect of
asthma medications.39,41 This is signiﬁcant given that
patients’ belief in their medication and the importance of
inhaler use is associated with adherence.42 Other factors
linked with non-adherence in adolescents include forgetful-
ness and being too busy to take medication.14,41,43
Adolescents surveyed about their asthma medication use
Table 1 Factors Affecting Asthma Medication Non-Adherence
General Factors Adolescent-Speciﬁc Factors
● Inadequate instructions or complex/time-consuming regimen ● Desire for independence and responsibility, including rejection of
parental monitoring and support
● Lackof structured home environment/routine, including hectic schedules ● Parent–child conﬂict and confusion over who is responsible for ensur-
ing that medications are taken correctly
● Lack of communication/coordination between patients and caregivers ● Difﬁculties in organizing time and setting priorities
● Insufﬁcient education and negative perceptions about treatment, eg,
unpalatable taste, fear of side effects and concerns about addiction/
dependence
● Forgetfulness or being too busy to take medication
● Incorrect inhaler use ● Lack of engagement in decision-making around medication use
● Lack of awareness of difference between rescue and controller
medication
● Overreliance on parents/caregivers coupled with lack of parental
motivation, eg, due to emotional/ﬁnancial burden or maternal
depression
● Unwillingness to take medication to prevent or reduce future risks
rather than to address immediate symptoms
● Lack of trust or poor rapport between patients and HCPs ● Not being motivated to take medication or considering regimen to be
too time-consuming or to conﬂict with other activities
● Inability to recognize asthma symptoms or tolerance of asthma
symptoms that most HCPs would ﬁnd unacceptable
● Lack of perceived effect of asthma medications
● Impact of mental health, eg, depression and anxiety ● Social stigma/embarrassment in front of friends
● Risk-taking behaviors such as smoking, drinking alcohol and marijuana
use
● Increased impact of mental health disorders in adolescents
Abbreviation: HCP, healthcare practitioner.
Dovepress Kaplan and Price
Journal of Asthma and Allergy 2020:13 submit your manuscript | www.dovepress.com
DovePress
43
 
Jo
ur
na
l o
f A
st
hm
a 
an
d 
Al
le
rg
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
96
.1
24
 o
n 
18
-F
eb
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
cited “feeling well” and “having no symptoms” as reasons
for forgetting to take medications, whereas others attributed
it to difﬁculties in organizing time and setting priorities.14
The perceived social stigma of having an illness may also
have a contributing effect on why adolescents choose not to
use their inhalers, especially in public or in front of their
peers.5 Insights from adolescents suggest a sense of denial
over their asthma and an unwillingness to be treated differently
or to be labeled as “an ill person” or “an asthmatic”.5 Stigma
around using inhalers can affect adherence at the levels of
initiation, implementation or persistence.30 For adolescents
with asthma, embarrassment in front of friends is
a predominant reason for non-adherence, including a desire
to hide their condition and treatment from their peers.5,13
A study in the US found that, among adolescents, approxi-
mately 50% of non-adherence occurred in the presence of
friends.44
Risk-taking behaviors such as smoking, drinking alco-
hol and marijuana use can also have a signiﬁcant negative
impact on adherence. In a survey of adolescents by the
Centers for Disease Control and Prevention in the US,
students reporting current asthma had a greater frequency
of depressive symptoms, cigarette smoking and cocaine
use than their asthma-free peers.45 Behaviors such as
smoking and drinking can be interpreted as a sign of
general disregard for one’s health, and this often extends
to adherence.46 A study examining the circumstances sur-
rounding 21 asthma-related deaths of children and adoles-
cents found the risk proﬁle included depressive symptoms
in adolescents, family dysfunction, parental psychopathol-
ogy, alcoholism, and lack of self-care and adherence.47
Children and adolescents with symptomatic asthma are
also reported to be more likely to suffer from mental
health disorders compared with their healthy peers,
which in turn has an impact on adherence.32 The evidence
to date implies that the development of asthma may pre-
dispose patients to depression, anxiety and other mood
disorders, and that these may in turn inﬂuence disease
severity and control.32 Reports from caregivers suggest
that over 40% of children and adolescents with asthma
aged 6–16 years have major or minor psychosocial pro-
blems, representing a doubling compared with the general
population, which will, in turn, have a knock-on effect
upon adherence.48
Consequences of Non-Adherence
The main consequence of non-adherence to asthma medi-
cations is a decrease in asthma control, leading to poor
symptom control, higher rates of exacerbations and
reduced quality of life.18,30,49 The relationship between
good adherence and decreased frequency of exacerbations
is well established, with the primary treatment beneﬁt seen
in patients with >75–80% adherence.29 However, given
that adherence is considerably lower than this according
to most studies carried out in adolescents, the impact on
asthma control may be substantial.
Uncontrolled asthma resulting from inadequate adher-
ence and other factors is a major cause of mortality and
disability, particularly in children and adolescents.18 Non-
adherence can also lead to a signiﬁcant increase in health-
care utilization and costs, including hospitalizations and
emergency department visits, due to lack of asthma
control.49,50 This may include increased use of oral corti-
costeroids, which can have both short- and long-term
adverse consequences.51 If non-adherence remains unde-
tected, the dose of medication may be increased or extra
treatment may be prescribed unnecessarily in order to try
to achieve disease control, thus further increasing the cost
and complexity of the regimen.22 Other consequences may
include sleep disruption and a limited ability to do sports
or recreational activities.50 Poorly controlled asthma is
also one of the leading causes of school absenteeism in
the US annually, with a total of 13.8 million missed school
days reported in 2013.52
Possible Solutions to
Non-Adherence
Improving Inhaler Technique
Poor inhaler instruction and technique represent
a fundamental cause of asthma medication non-
adherence, resulting in ineffective drug delivery to the
lungs and a reduction in medication efﬁcacy.30
Improving understanding of the need for inhaled therapy
and advice on optimal technique for using the inhaler
device should increase patient adherence.30
HCPs can help to improve adherence by ensuring that
they have good knowledge across a range of inhaler
devices and device types, so that they can advise their
patients optimally.30 Assessments of inhaler technique,
using checklists of critical inhaler errors as a guide, should
be carried out regularly, and retraining and/or alternative
treatment options considered where appropriate.30,53 The
CRITical Inhaler mistaKes and Asthma controL
(CRITIKAL) study identiﬁed certain inhaler errors that
were considered to be the most important, based on their
Kaplan and Price Dovepress
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impact on asthma outcomes.54 For example, insufﬁcient
inspiratory effort (reported in 32–38% of dry-powder inha-
ler users) was associated with uncontrolled asthma and
increased exacerbation rate, and actuation before inhala-
tion (reported in 24.9% of metered-dose inhaler users) was
associated with uncontrolled asthma.55 It is therefore
important that primary and secondary care management
of asthma should implement inhaler training to speciﬁcally
target these critical errors.55
Choosing the Most Appropriate Inhaler
Patient preference for and satisfaction with speciﬁc inhaler
devices also correlates with improved adherence and clin-
ical outcomes.11,56 Some studies suggest that speciﬁc inha-
ler types may be associated with better adherence,
although further investigation is needed to conﬁrm this.56
Many factors, including age, dexterity, inspiratory
capacity, cognitive ability, health literacy and ethnicity,
affect the ability and motivation of patients to use their
inhaler devices, and it is therefore imperative that the most
appropriate inhaler device to suit each individual patient is
chosen in order to improve adherence.54 This includes
taking into account patients’ demographic characteristics,
lifestyle and comorbidities, as well as patient
preferences.30,42,54 Features to consider include ease of
use (eg, learning to use, holding, operating and cleaning),
convenience (eg, size, color, shape, durability and weight)
and oral sensation (eg, taste and irritation).42 All adoles-
cents should be encouraged to use their metered-dose
inhaler with a spacer or else to use a dry-powder
inhaler.42,57 For this age group, in particular, regular
review by an HCP who has received inhalation technique
training is essential.42
Choosing the Most Appropriate
Medication
Choice of medication may also affect adherence; for
example, when comparing as-needed treatment with main-
tenance therapy. Results from the SYmbicort Given as
needed in Mild Asthma (SYGMA) program showed that
as-needed budesonide/formoterol combination therapy had
a comparable effect on exacerbations compared with main-
tenance budesonide (although with substantially lower
glucocorticoid exposure), and a superior effect on both
symptoms and exacerbations versus terbutaline therapy in
patients with mild asthma.58,59 This approach represents
an alternative treatment option for patients with mild
asthma who may rely too heavily on short-acting β2-
agonist (SABA) reliever medication – which does not
address underlying inﬂammation – and who may be less
adherent with maintenance therapy.60 In support of this,
the 2019 GINA recommendations include as-needed ICS/
formoterol for adolescents and adults with mild asthma.8
Enhancing Collaboration with HCPs
Adherence also improves when physicians and patients
collaborate to ensure comprehensive understanding of
asthma and the necessary treatment.61,62 A model of how
clinicians and patients with asthma can collaborate effec-
tively is shown in Figure 2.
Clear and open patient–physician communication that
builds empathy and incorporates motivational interviewing
techniques and shared decision-making/treatment goals is
vital, particularly for adolescents.62 This approach can
address patient-speciﬁc concerns, evaluate their beliefs,
engage patients in the management of their disease, and
ensure family members are educated and able to support
the patient. Understanding is key in order to recognize any
symptom changes and to adjust treatment, or switch to
available treatment alternatives according to guidelines. It
is also important to ensure that regular follow-up appoint-
ments are arranged with the treating physician, with
reminders and other organizational factors to help improve
adherence.62
Other Strategies
Given the poor adherence of adolescents to their asthma
regimens, one approach that may help to support behavior
modiﬁcation is the routine identiﬁcation of non-adherent
patients.26 Several methods of adherence monitoring are
available, each with a unique set of advantages and dis-
advantages. These include subjective monitoring tools (for
example, physician assessment of adherence, parental/
child assessment of adherence, or self-report question-
naires such as the Morisky scale, Medicines Adherence
Report Scale – Asthma, Test of the Adherence to Inhalers
and Beliefs About Medication Questionnaire).26,63,64 In
addition, a questionnaire has recently been developed
that is speciﬁc to adolescents with asthma, called the
Adolescent Asthma Self-Efﬁcacy Questionnaire.65
Objective monitoring approaches are also available,
including analysis of prescription data, weighing inhaler
canisters, dose counters, directly observed therapy and
nurse home visits.26 Meanwhile, other approaches are
being evaluated, including reminder-based systems (eg,
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Figure 2 Model of clinician–patient partnership in asthma. Reprinted from Clinical Pediatrics, 47 (1), Clark et al, The Clinician-Patient Partnership Paradigm: Outcomes
Associated With Physician Communication Behavior, 49–57, 2017, with permission from SAGE Publications.
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electronic medical record reminders), the integration of
digital technologies (eg, sensors from Adherium,
Propeller Health and Timestamp66), controller apps and
biomarkers of adherence.26, 62,67,68
The current gold standard method of measuring adher-
ence – electronic monitoring – assesses when and how
often patients activate their inhaler, with the potential to
download data using smartphone applications.26 Although
electronic monitoring devices are widely regarded as the
most accurate and objective measure of recording medica-
tion use, many of them have drawbacks, including cost
and a lack of information on inhaler technique or why
patients are non-adherent.26 However, ﬁndings from
a survey show that this is a popular approach with adoles-
cents, enabling them to achieve a greater degree of respon-
sibility and independence,69 and some models (such as the
INCA device) have been adapted to include sensors that
can monitor inhalation.26 Electronic monitoring also has
an important role in determining future management, both
in terms of tailoring adherence interventions and in sup-
porting decision-making regarding treatment changes.70
Management needs to focus on and address the reasons
for poor adherence rather than simply escalating the pre-
scribed treatment.70 Importantly, electronic monitoring can
help to identify those people with poor asthma control
despite good adherence who may be eligible for more
expensive therapies, such as biologics.70
Other approaches that adolescents suggest may help to
inﬂuence adherence include peer support, medication
reminders (preferably via smartphone applications) and
user-friendly online support systems with messaging
functionality.41,71 In addition, routine screening for depres-
sion and other mood/mental disorders may also result in
better asthma control71 and thus increase adherence.
Conclusion
Medication adherence in adolescents with asthma faces
many challenges. Identifying the reasons for poor disease
control and adherence is essential in order to help improve
patient quality of life.
Patient/HCP communication is a key component for
effective and comprehensive patient assessment and for
tailoring treatment to individual requirements.
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